Considerable changes have occurred in the management of differentiated thyroid cancer
(DTC) during the past four decades, based on improved knowledge of the biology of DTC …

Background: Thyroid nodules are a common clinical problem, and differentiated thyroid
cancer is becoming increasingly prevalent. Since the American Thyroid Association's …

Modern use of post-operative radioactive iodine (RAI) treatment for differentiated thyroid
cancer (DTC) should be implemented in line with patients' risk stratification. Although …

Background: Publication of the 2015 American Thyroid Association (ATA) management
guidelines for adult patients with thyroid nodules and differentiated thyroid cancer was met …

Substantial developments have occurred in the past 5–10 years in clinical translational
research of thyroid cancer. Diagnostic molecular markers, such as RET-PTC, RAS, and …

THERAPY OF THYROID DISEASE WITH 131I• Silberstein et al. 1633 patients throughout
the United States. Existing practice guidelines will be reviewed for revision or renewal, as …

Radioiodine (131I) therapy of benign thyroid diseases was introduced 70 yr ago, and the
patients treated since then are probably numbered in the millions. Fifty to 90% of …

In many parts of the world, incidence of papillary thyroid cancer is increasing faster than any
other malignancy. Most papillary thyroid cancers that are diagnosed are small and are …

Background: Radioiodine remnant ablation (RRA) has traditionally been one of the
cornerstones of differentiated thyroid cancer (DTC) treatment. The decision to use RRA in …

Abstract BACKGROUND: American Thyroid Association guidelines currently recommend the
selective use of radioactive iodine (RAI) therapy in patients with well differentiated thyroid …